These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7822705)

  • 1. [Tamoxifen in the treatment of breast cancer].
    Charlier C; Colin C; Merville MP; Gielen J; Lambotte R; Plomteux G; Castronovo V
    J Gynecol Obstet Biol Reprod (Paris); 1994; 23(7):751-6. PubMed ID: 7822705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
    Boylan M; van den Berg HW; Lynch M
    Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?
    Wakeling AE
    J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):107-14. PubMed ID: 8274423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The elucidation of the antiestrogen and antitumoral mechanisms of tamoxifen].
    Borgna JL
    Bull Cancer; 1994 Jan; 81(1):29-37. PubMed ID: 7949581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Pathol Biol (Paris); 1983 Nov; 31(9):775-81. PubMed ID: 6361675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches.
    de Cupis A; Schettini G; Favoni RE
    Pharmacol Res; 1999 May; 39(5):335-44. PubMed ID: 10328990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells.
    Sutherland RL; Watts CK; Hall RE; Ruenitz PC
    J Steroid Biochem; 1987; 27(4-6):891-7. PubMed ID: 3695509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing role of the oestrogen receptor in the life and death of breast cancer cells.
    Jordan VC; Osipo C; Schafer JM; Fox JE; Cheng D; Liu H
    Breast; 2003 Dec; 12(6):432-41. PubMed ID: 14659118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Müller V; Jensen EV; Knabbe C
    Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
    Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
    Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular strategy to control tamoxifen resistant breast cancer.
    Jiang SY; Jordan VC
    Cancer Surv; 1992; 14():55-70. PubMed ID: 1423331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer chemoprevention.
    Costa A
    Eur J Cancer; 1993; 29A(4):589-92. PubMed ID: 8382073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a molecular basis for tamoxifen resistance in breast cancer.
    Johnston SR; Dowsett M; Smith IE
    Ann Oncol; 1992 Jul; 3(7):503-11. PubMed ID: 1498070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of a tamoxifen-resistant breast carcinoma xenograft.
    Naundorf H; Becker M; Lykkesfeldt AE; Elbe B; Neumann C; Büttner B; Fichtner I
    Br J Cancer; 2000 Jun; 82(11):1844-50. PubMed ID: 10839300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen.
    Benson JR; Wakefield LM; Baum M; Colletta AA
    Br J Cancer; 1996 Aug; 74(3):352-8. PubMed ID: 8695348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.